↓ Skip to main content

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Overview of attention for article published in New England Journal of Medicine, November 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

news
12 news outlets
blogs
3 blogs
policy
2 policy sources
twitter
86 X users
patent
8 patents
facebook
8 Facebook pages
wikipedia
2 Wikipedia pages
googleplus
1 Google+ user
reddit
1 Redditor
guideline
8 clinical guideline sources
podcasts
1 podcast

Readers on

mendeley
384 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 86 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 384 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 384 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 63 16%
Other 49 13%
Student > Bachelor 31 8%
Student > Ph. D. Student 27 7%
Student > Doctoral Student 20 5%
Other 70 18%
Unknown 124 32%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 129 34%
Biochemistry, Genetics and Molecular Biology 33 9%
Pharmacology, Toxicology and Pharmaceutical Science 19 5%
Agricultural and Biological Sciences 13 3%
Immunology and Microbiology 8 2%
Other 43 11%
Unknown 139 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 190. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2026.
All research outputs
#263,663
of 34,421,733 outputs
Outputs from New England Journal of Medicine
#4,727
of 38,395 outputs
Outputs of similar age
#4,340
of 396,326 outputs
Outputs of similar age from New England Journal of Medicine
#96
of 279 outputs
Altmetric has tracked 34,421,733 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 38,395 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 120.2. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 396,326 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 279 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.